復(fù)方黨參片信息，PDF格式或照片均可   [更多]

標(biāo)題：1000元懸賞提取國外上市醫(yī)藥企業(yè)年報中產(chǎn)品銷售數(shù)據(jù) 需求名稱：年報數(shù)據(jù)處理 價格預(yù)算：200元/人 詳細(xì)要求： ① 從任務(wù)主手中獲取指定企業(yè)的年報文件， ② 將年報中的相應(yīng)數(shù)據(jù)填入相應(yīng)表格，年報中沒有的數(shù)據(jù)表格相應(yīng)內(nèi)容不做填寫， ③ 要求仔細(xì)認(rèn)真，熟悉英文或?qū)Ψg工具的熟練使用， ④ 價格5元/個（填寫完了審核通過，每個年報要求把所有產(chǎn)品銷售額收集填寫完）， ⑤ 如若審核發(fā)現(xiàn)有填錯，填漏；以每填錯，填漏一個數(shù)據(jù)1元計量扣除賞金。 交稿方式：請將數(shù)據(jù)表格直接打包在藥智網(wǎng)交稿就可以了 交稿時間：可與任務(wù)主協(xié)商實際交稿時間。   [更多]

標(biāo)題： 1、January 8, 1982 Cough Variant Asthma in Children Paul J. Hannaway, MD; G. David K. Hopper, MD JAMA. 1982;247(2):206-208. doi:10.1001/jama.1982.03320270044023 2、J Dig Dis. 2018 Feb 1. doi: 10.1111/1751-2980.12583. [Epub ahead of print] Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. 3、Brexit from current guideline recommendations 4、Tolvaptan in Chinese cirrhotic patients with ascites: a randomized, placebo-controlled phase 2 trial 5、Increased serum c-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tovaptan in patients with liver cirrhosis 6、In vitro p-glycoproten interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. 7、Pharmacokinetics and pharmacodynamics interaction between tolvaptan and warfarin in healthy subjects 8、Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects 9、7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoy-amino)benzoy]-2,3,4,5-tetrahydro-1H-1-benzazepine(OPC-41061): a potent, orally active nonpeptide arginine vasorpressin V2 receptor antagonist 10:33:17   [更多]

高價求購《預(yù)充式導(dǎo)管沖洗器》相關(guān)信息，內(nèi)容要清晰，價格好商量。。。。   [更多]

藥智網(wǎng)建有一個中標(biāo)數(shù)據(jù)庫http://db.yaozh.com/yaopinzhongbiao.html收集了全國各省市的藥品中標(biāo)信息，為了保證給大家有更準(zhǔn)確及時的信息，需要對藥品中標(biāo)信息數(shù)據(jù)庫及時更新，現(xiàn)請人進行最新中標(biāo)數(shù)據(jù)的收集整理。 工作內(nèi)容：及時查到最新公布的藥品中標(biāo)信息，并將最新的文件按指定要求處理成規(guī)范的格式(excel表)。交稿如發(fā)現(xiàn)遺漏，反饋后望及時補充。 不是一次性任務(wù)。長期合作(一年以上)   [更多]

《預(yù)沖式?jīng)_管注射器》信息   [更多]

求鹽酸土霉素BP2017一份   [更多]

標(biāo)題： 1、PMID：29241352 Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: a case report 2、PMID：18306096 Hyponatremia in psychiatric patients: update on evaluation and management 3、PMID：20643634 The assessment and treatment of water imbalance in patients with psychosis 4、Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival anti-oxidant. Antioxid Redox Signal. (2009) 11(11)2685-700 5、Yeni D;Effect of α-lipoic acid on sperm quality, reproductive tract measures in thinner exposed rats. 6、PRELIMINARY BASELINE DATA OF HYPERTENSIVE PATIENTS INCLUDED IN THE CATCH (CANDESARTAN ASSESSMENT IN THE TREATMENT OF CARDIAC HYPERTROPHY) STUDY: P1.195 7、Synthesis and antibacterial activity of 1-cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carb oxylic acid 8、Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients: Expert Review of Clinical Pharmacology: Vol 10, No 7 9、Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. - PubMed - NCBI 10、 Huiming Ma.Protective function of alpha-lipoic acid on sperm motility and mitochondrial function during goat sperm-mediated gene transfer[J].Small Ruminant Research 99 (2011) 191-198 11、The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). 12、Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. 將符合標(biāo)題的文獻PDF格式上傳，按照交稿時間的先后確認(rèn)稿件，先到先得   [更多]

復(fù)方蓯蓉益智膠囊現(xiàn)行信息，現(xiàn)行的信息原文，PDF格式或照片均可   [更多]

1. 熟悉PDF編輯技巧(去水印、去章印、增刪內(nèi)容) 2. 處理完213個PDF上面的水印標(biāo)記和部分與文章標(biāo)題無關(guān)的內(nèi)容，提交后待成品效果符合要求后才判為合格，否則為不合格任務(wù)（具體處理細(xì)則可以QQ咨詢） 3. 需處理的PDF文檔待接下任務(wù)后再提供 4. 以前投過稿且完成效果較好的優(yōu)先考慮   [更多]